Posted in Press Releases

SEATTLE, April 30, 2019 — Safety, Tolerability and Comparative Bioavailability Data Support INP104, Impel’s Nasal Drug Candidate for Acute Migraine Results from the Company’s Phase 3 Clinical Program Evaluating INP104 for the Treatment of Acute Migraine Anticipated in Late 2019 Preclinical Data Support Selection of Company’s Novel Formulation of Nasal Levodopa,...

Posted in Press Releases

Crossover Financing to Advance Clinical Development of Central Nervous System Assets in Migraine, Parkinson’s Disease and Acute Agitation SEATTLE, December 6th, 2018 — Impel NeuroPharma (“Impel” or the “Company”), a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system (“CNS”) disorders with unmet medical needs,...

Posted in Press Releases

SEATTLE, Nov. 7, 2018 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system (CNS) disorders with unmet medical needs, today announced the appointment of Ellen A. Lubman as Chief Business Officer. In her role, Ellen's primary responsibilities are to...

Posted in Press Releases

Study to Establish Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Olanzapine Delivered via Precision Olfactory Delivery (POD®) Device SEATTLE, August 29, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced the first subject has been dosed in a...

Posted in Press Releases

Safety and Tolerability of POD-DHE (STOP-301) Trial to Explore Safety and Tolerability of Long-Term Intermittent Use of Intranasal Dihydroergotamine Mesylate Delivered via Precision Olfactory Delivery (POD®) Device STOP-301 Trial Recruiting More Quickly Than Expected, Company On-Track With 2019 NDA Filing SEATTLE, August 22, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company...

Posted in Press Releases

SEATTLE, July 16, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that Lynn C. Gold, Ph.D., has joined the Company as the Senior Vice President of Regulatory Affairs. In this capacity, Gold has extensive oversight of regulatory...

Posted in Press Releases

SEATTLE, June 26, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced new data from the Company’s investigational drug INP104 for acute migraine will be presented at the American Headache Society’s 60th Annual Meeting, June 28...

Posted in Press Releases

SEATTLE, June 22, 2018 — Impel NeuroPharma today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with its clinical investigation of INP104, a novel, dihydroergotamine (DHE) product dosed via Impel’s proprietary Precision Olfactory Delivery, or POD®, intranasal delivery device for the treatment...

Categories